Synthesis, Characterization, and X-Ray Structures of 2-(3,5-Dimethylpyrazol-1-Yl)Phenyl-Based Organoselenium Compounds and Their Glutathione Peroxidase (Gpx) Like Activity

Hydrogen-bonded linear chain assemblies of palladium(II)-selenoether complexes: solid state aggregates as templates for nano-structural Pd17Se15 leading to efficient electrocatalytic activity

A analogous series of 2-(3,5-dimethylpyrazol-1-yl)phenyl substituted selenoether complexes of palladium [PdCl2(RSeC6H4dmpz)]; (R = CH2COOH (1), CH2CH2COOH (2), and CH2CH2OH (3); dmpz = dimethylpyrazole) were ably synthesized in a facile manner and exhaustively characterized. Insight into molecular structures of these complexes was keenly probed through single crystal X-ray diffraction (XRD) analysis, unfolding the structural scaffolds and laying into molecular aggregation, availed through hydrogen bonding interactions borne out of tethered protic groups. The complexes were converted to capping free palladium selenide (Pd17Se15) nanoparticles through pyrolysis and evaluated for their electrocatalytic efficacy towards the hydrogen evolution reaction (HER), the oxygen evolution reaction (OER) and methanol oxidation reaction (MOR) in alkaline medium. In an alkaline medium, PSNP1 (Pd17Se15) obtained from the hydrogen bonded aggregate of complex PdCl2L1 (1) produced good HER activity. PSNP1 had a little decrease in current density after 300 continuous cycles, which proves that the catalyst presents high stability in the recycling process. For the electrocatalytic oxidation of CH3OH, the electrocatalytic rate constant (k) obtained was 0.3 × 103 cm3 mol-1 s-1.

Toxicology and pharmacology of synthetic organoselenium compounds: an update

Here, we addressed the pharmacology and toxicology of synthetic organoselenium compounds and some naturally occurring organoselenium amino acids. The use of selenium as a tool in organic synthesis and as a pharmacological agent goes back to the middle of the nineteenth and the beginning of the twentieth centuries. The rediscovery of ebselen and its investigation in clinical trials have motivated the search for new organoselenium molecules with pharmacological properties. Although ebselen and diselenides have some overlapping pharmacological properties, their molecular targets are not identical. However, they have similar anti-inflammatory and antioxidant activities, possibly, via activation of transcription factors, regulating the expression of antioxidant genes. In short, our knowledge about the pharmacological properties of simple organoselenium compounds is still elusive. However, contrary to our early expectations that they could imitate selenoproteins, organoselenium compounds seem to have non-specific modulatory activation of antioxidant pathways and specific inhibitory effects in some thiol-containing proteins. The thiol-oxidizing properties of organoselenium compounds are considered the molecular basis of their chronic toxicity; however, the acute use of organoselenium compounds as inhibitors of specific thiol-containing enzymes can be of therapeutic significance. In summary, the outcomes of the clinical trials of ebselen as a mimetic of lithium or as an inhibitor of SARS-CoV-2 proteases will be important to the field of organoselenium synthesis. The development of computational techniques that could predict rational modifications in the structure of organoselenium compounds to increase their specificity is required to construct a library of thiol-modifying agents with selectivity toward specific target proteins.

Organoselenium compounds as mimics of selenoproteins and thiol modifier agents

Selenium is an essential trace element for animals and its role in the chemistry of life relies on a unique functional group: the selenol (-SeH) group. The selenol group participates in critical redox reactions. The antioxidant enzymes glutathione peroxidase (GPx) and thioredoxin reductase (TrxR) exemplify important selenoproteins. The selenol group shares several chemical properties with the thiol group (-SH), but it is much more reactive than the sulfur analogue. The substitution of S by Se has been exploited in organic synthesis for a long time, but in the last 4 decades the re-discovery of ebselen (2-phenyl-1,2-benzisoselenazol-3(2H)-one) and the demonstration that it has antioxidant and therapeutic properties has renovated interest in the field. The ability of ebselen to mimic the reaction catalyzed by GPx has been viewed as the most important molecular mechanism of action of this class of compound. The term GPx-like or thiol peroxidase-like reaction was previously coined in the field and it is now accepted as the most important chemical attribute of organoselenium compounds. Here, we will critically review the literature on the capacity of organoselenium compounds to mimic selenoproteins (particularly GPx) and discuss some of the bottlenecks in the field. Although the GPx-like activity of organoselenium compounds contributes to their pharmacological effects, the superestimation of the GPx-like activity has to be questioned. The ability of these compounds to oxidize the thiol groups of proteins (the thiol modifier effects of organoselenium compounds) and to spare selenoproteins from inactivation by soft-electrophiles (MeHg⁺, Hg²⁺, Cd²⁺, etc.) might be more relevant for the explanation of their pharmacological effects than their GPx-like activity. In our view, the exploitation of the thiol modifier properties of organoselenium compounds can be harnessed more rationally than the use of low mass molecular structures to mimic the activity of high mass macromolecules that have been shaped by millions to billions of years of evolution.